GBIM:OTCMKTS
GlobeImmune Inc
0,00010 $
0,00%
(0,00) 1 p
29. sept, 15:48:52 GMT −4 · USD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GBIM põhistatistika genereerimine…
Turu kapit.
580,00
Keskm. maht
1,74 tuh
Maht
0,00
52 näd kõrgeim
0,04 $
52 näd madalaim
0,00 $
Käibivad aktsiad
5,75 mln
Töötajate arv
22
Turu kapit.
580,00
Keskm. maht
1,74 tuh
Maht
0,00
52 näd kõrgeim
0,04 $
52 näd madalaim
0,00 $
Käibivad aktsiad
5,75 mln
Töötajate arv
22
Uudised
Veebiallikatest ja uudistepartneritelt
Ärileht
·
1 päeva eest
Mida sa investeerides tegelikult ostad? Paljude lemmik naudib erakordselt head aega
Business Wire
·
31 minuti eest
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TradingView
·
23 minuti eest
Iambic Therapeutics, AI-Driven Drug Discovery and Development, Files for Nasdaq Global Select Market IPO
Profiil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Teave üksuse GlobeImmune Inc kohta
Tegevjuht-
Töötajad22
Asutatud1. jaan 1995
PeakontoridLouisville, Colorado, Ameerika Ühendriigid
Sektor-
Veebisaitglobeimmune.com